Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
7
×
boston top stories
life sciences
national blog main
fda
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston
deals
eli lilly
national
biontech
bristol-myers squibb
cancer
drugs
immunotherapy
investing
loxo oncology
merck
What
time
7
×
fda
approved
bio
cancer
days
deal
drug
friday
medicine
new
rna
second
acquire
adding
agency
ago
aimmune
airport
allergy
alliance
alnylam
annual
apocalypse
approval
approve
atrial
awaits
awarded
beds
bets
biological
boston
bristol
business
buy
calls
celgene
changing
color
Language
unset
Current search:
time
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines